Format

Send to

Choose Destination
Chem Res Toxicol. 2012 Mar 19;25(3):532-42. doi: 10.1021/tx2005212. Epub 2012 Feb 28.

Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.

Author information

1
CVGI iMed DMPK, ADME Section, Centre of Excellence, AstraZeneca R&D, Mölndal, SE 431 83 Sweden. Emre.Isin@astrazeneca.com

Abstract

As part of the drug discovery and development process, it is important to understand the fate of the drug candidate in humans and the relevance of the animal species used for preclinical toxicity and pharmacodynamic studies. Therefore, various in vitro and in vivo studies are conducted during the different stages of the drug development process to elucidate the absorption, distribution, metabolism, and excretion properties of the drug candidate. Although state-of-the-art LC/MS techniques are commonly employed for these studies, radiolabeled molecules are still frequently required for the quantification of metabolites and to assess the retention and excretion of all drug related material without relying on structural information and MS ionization properties. In this perspective, we describe the activities of Isotope Chemistry at AstraZeneca and give a brief overview of different commonly used approaches for the preparation of (14)C- and (3)H-labeled drug candidates. Also various drug metabolism and pharmacokinetic studies utilizing radiolabeled drug candidates are presented with in-house examples where relevant. Finally, we outline strategic changes to our use of radiolabeled compounds in drug metabolism and pharmacokinetic studies, with an emphasis on delaying of in vivo studies employing radiolabeled drug molecules.

PMID:
22372867
DOI:
10.1021/tx2005212
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center